We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About AiCure Stock

Invest in or calculate the value of your shares in AiCure or other pre-IPO companies through EquityZen's platform.

Get Started

AiCure Stock (AICU)

AiCure's intelligent medical assistant, IMA, leverages a visual recognition platform to monitor patient progress.

About AiCure Stock

Founded

2010

Headquarters

New York, NY, US

Total Funding

27.3M

Industries

Software, Artificial Intelligence, Data and Analytics

AiCure's intelligent medical assistant, IMA, leverages a visual recognition platform to monitor patient progress. IMA provides visual dose confirmation, interactive patient support and engagement, and visual diagnostic capabilities. The platform has been validated to improve patient behavior in randomized controlled trials. In clinical research, AiCure is increasing the probability of trial success and introducing more objective clinical endpoints. In population health, AiCure is enabling intelligent decision-making and improving health outcomes. By 2020, there will be a one million nurse shortage in the US. AiCure is striving to help fill this gap. In clinical research, approximately one quarter of clinical trials fail due to a lack of patient oversight, contributing to over $40 billion in annual losses. AiCure is seeking to accelerate better medications into the market.

AiCure Press Mentions

Stay in the know about the latest news on AiCure

AiCure Management

Leadership team at AiCure

Chief Product Officer

Michelle Marlborough

Co-Founder & CSO

Laura Shafner

Locked Features

Join now and verify your accreditation status to gain access to:

  • AiCure current valuation
  • AiCure stock price
  • Available deals in AiCure and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in AiCure stock?

Accredited investors can buy pre-IPO stock in companies like AiCure through EquityZen funds. These investments are made available by existing AiCure shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell AiCure stock?

Shareholders can sell their AiCure stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."